Top

BMC Cancer

Published in:

Open Access 01-12-2012 | Research article

Insulin-like growth factors in endometrioid adenocarcinoma: Correlation with clinico-pathological features and estrogen receptor expression

Authors: Yuan-Jiao Liang, Qun Hao, Hui-Ming Zhang, Yuan-Zhe Wu, Jian-Dong Wang

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

Endometrial carcinoma is a common malignancy of female genital tract. Insulin-like growth factor is known to elicit estrogen-induced mitogenic activity and anti-apoptotic effect in endometrial tissues.

Methods

The retrospective study investigated the expression of insulin-like growth factors, estrogen receptors and their associations in endometrioid adenocarcinoma (EAC) from 80 EAC patients in immunohistochemistry, and 58 EAC patients and 42 control patients in quantitative RT-PCR. The Pearson correlation analysis was used to analyze their correlations with clinic-pathological parameters.

Results

Our results showed that insulin-like growth factor-1 and insulin-like growth factor-2 mRNA levels were higher in tumor tissues and tumor-adjacent tissues than those in control cells, and were inversely correlated with the malignancy of the tumor with a positive correlation with ERα and ERβ expression. Insulin-like growth factor-1R protein expression was correlated with clinical stage, and insulin-like growth factor-2R protein expression was inversely correlated with histological grade.

Conclusions

Insulin-like growth factor system plays an important role in estrogen-induced endometrial carcinogenesis, and overexpression of insulin-like growth factor-1R in the advanced endometrioid adenocarcinoma is not estrogen-dependent.

Available only for authorised users

Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed

Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S105-S143.CrossRefPubMed

Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P: Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci. 2001, 943: 296-315.CrossRefPubMed

Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR: Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA. 1997, 94 (12): 6535-6540. 10.1073/pnas.94.12.6535.CrossRefPubMedPubMedCentral

Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE: Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol. 1988, 31 (1): 65-81. 10.1016/0090-8258(88)90270-3.CrossRefPubMed

Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL: Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996, 63 (1): 28-33. 10.1006/gyno.1996.0273.CrossRefPubMed

Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993, 71 (4 Suppl): 1467-1470.CrossRefPubMed

Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S: Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer. 2007, 17 (4): 905-913. 10.1111/j.1525-1438.2006.00851.x.CrossRefPubMed

Mylonas I: Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep. 2010, 24 (2): 385-393.CrossRefPubMed

10.

Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S: Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol. 2008, 16 (6): 535-542. 10.1097/PAI.0b013e31816755a9.CrossRefPubMed

11.

Reynolds RK, Hu C, Baker VV: Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines. Gynecol Oncol. 1998, 70 (2): 202-209. 10.1006/gyno.1998.5089.CrossRefPubMed

12.

McCampbell AS, Broaddus RR, Loose DS, Davies PJ: Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006, 12 (21): 6373-6378. 10.1158/1078-0432.CCR-06-0912.CrossRefPubMed

13.

Murphy LJ, Ghahary A: Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev. 1990, 11 (3): 443-453. 10.1210/edrv-11-3-443.CrossRefPubMed

14.

Rutanen EM, Nyman T, Lehtovirta P, Ammala M, Pekonen F: Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer. 1994, 59 (3): 307-312. 10.1002/ijc.2910590303.CrossRefPubMed

15.

Pavelic J, Radakovic B, Pavelic K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol. 2007, 105 (3): 727-735. 10.1016/j.ygyno.2007.02.012.CrossRefPubMed

16.

Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A, Rutanen EM: Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas. 1995, 22 (3): 255-262. 10.1016/0378-5122(95)00935-E.CrossRefPubMed

17.

Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al: Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007, 43 (16): 2434-2444. 10.1016/j.ejca.2007.08.014.CrossRefPubMed

18.

Pavelic J, Matijevic T, Knezevic J: Biological & physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res. 2007, 125 (4): 511-522.PubMed

19.

Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V, et al: Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003, 104 (5): 636-642. 10.1002/ijc.10990.CrossRefPubMed

20.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, et al: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17 (4): 921-929. 10.1158/1055-9965.EPI-07-2686.CrossRefPubMedPubMedCentral

21.

Hamelers IH, Steenbergh PH: Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer. 2003, 10 (2): 331-345. 10.1677/erc.0.0100331.CrossRefPubMed

22.

Zhu L, Pollard JW: Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci USA. 2007, 104 (40): 15847-15851. 10.1073/pnas.0705749104.CrossRefPubMedPubMedCentral

23.

Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M: Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 2001, 61 (19): 7318-7324.PubMed

24.

LeRoith D, Roberts CT: The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195 (2): 127-137. 10.1016/S0304-3835(03)00159-9.CrossRefPubMed

25.

Larsson O, Girnita A, Girnita L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005, 92 (12): 2097-2101. 10.1038/sj.bjc.6602627.CrossRefPubMedPubMedCentral

26.

Oka Y, Waterland RA, Killian JK, Nolan CM, Jang HS, Tohara K, Sakaguchi S, Yao T, Iwashita A, Yata Y, et al: M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology. 2002, 35 (5): 1153-1163. 10.1053/jhep.2002.32669.CrossRefPubMed

27.

Jamieson TA, Brizel DM, Killian JK, Oka Y, Jang HS, Fu X, Clough RW, Vollmer RT, Anscher MS, Jirtle RL: M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer. 2003, 3: 4-10.1186/1471-2407-3-4.CrossRefPubMedPubMedCentral

28.

Kashima H, Shiozawa T, Miyamoto T, Suzuki A, Uchikawa J, Kurai M, Konishi I: Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr Relat Cancer. 2009, 16 (1): 113-122.CrossRefPubMed

29.

Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P: Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem. 2001, 276 (33): 31238-31246. 10.1074/jbc.M103634200.CrossRefPubMed

30.

Lacey JV, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, et al: Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev. 2004, 13 (4): 607-612.PubMed

31.

McGrath M, Lee IM, Buring J, De Vivo I: Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol Oncol. 2011, 120 (2): 174-178. 10.1016/j.ygyno.2010.10.012.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/262/prepub

Title: Insulin-like growth factors in endometrioid adenocarcinoma: Correlation with clinico-pathological features and estrogen receptor expression
Authors: Yuan-Jiao Liang
Qun Hao
Hui-Ming Zhang
Yuan-Zhe Wu
Jian-Dong Wang
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-262

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer

Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death

Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study

Inhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice

Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer